Impact News +++ Breaking Down TeraWulf: 5 Analysts Share Their Views (Benzinga) +++ TERAWULF Aktie +4,15%

BRISTOL-MYERS Aktie

>BRISTOL-MYERS Aktienkurs

52.9 EUR +2.2% (TradegateBSX)

Ask: 52.89 EUR / 100 Stück

Bid: 52.68 EUR / 100 Stück

Tagesumsatz: 5694 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>BRISTOL-MYERS Performance

1 Woche: +2,9%

1 Monat: +13,9%

3 Monate: +24,5%

6 Monate: +29,6%

1 Jahr: -5,9%

laufendes Jahr: +14,8%

>BRISTOL-MYERS Aktie

Name:

BRISTOL-MYERS SQUIBBDL-10

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US1101221083 / 850501

Symbol/ Ticker:

BRM (Frankfurt) / BMY (NYSE)

Kürzel:

FRA:BRM, ETR:BRM, BRM:GR, NYSE:BMY

Index:

S&P500

Webseite:

https://www.bms.com/

Profil:

Bristol-Myers Squibb Company is a global biopharmaceutical firm founded in 1887 that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines worldwide. Its po..
>Volltext..

Marktkapitalisierung:

105762.16 Mio. EUR

Unternehmenswert:

136852.19 Mio. EUR

Umsatz:

40830.44 Mio. EUR

EBITDA:

16291.85 Mio. EUR

Nettogewinn:

5976.22 Mio. EUR

Gewinn je Aktie:

2.94 EUR

Schulden:

39936.63 Mio. EUR

Liquide Mittel:

8649.17 Mio. EUR

Operativer Cashflow:

11993.1 Mio. EUR

Bargeldquote:

0.46

Umsatzwachstum:

-12.05%

Gewinnwachstum:

Dividende je Aktie:

2.13 EUR

Dividendenrendite:

4.06%

Dividendenschätzung:

4.11%

Div. Historie:

02.01.26 - 0.5355€
03.10.25 - 0.53196€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

BRISTOL-MYERS, BRISTOL MYERS

Letzte Datenerhebung:

28.02.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 2036.47 Mio. St.

Frei handelbar: 99.81%

Leerverk. Aktien: 1.56%

Rückkaufquote: -

Mitarbeiter: 32500

Umsatz/Mitarb.: 1.26 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 1.31%

Bewertung:

KGV: 17.47

KGV lG: 9.75

KUV: 2.57

KBV: 6.66

PEG-Ratio: -

EV/EBITDA: 8.4

Rentabilität:

Bruttomarge: 65.89%

Gewinnmarge: 14.64%

Operative Marge: 31.36%

Managementeffizenz:

Gesamtkaprendite: 7.72%

Eigenkaprendite: 40.53%

>Anleihen

>Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>BRISTOL-MYERS Chart & Kurs - NYSE

>BRISTOL-MYERS News

28.02.26 - 01:00	Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note (Zacks)
	In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.37, marking a +2.08% move from the previous day....

27.02.26 - 18:12	Is Bristol-Myers Squibb Stock Underperforming the Nasdaq? (Barchart)
	Um den gesamten Artikel unter newsbreak.com zu lesen, klicken Sie bitte auf die Überschrift...

26.02.26 - 22:03

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights (Business Wire)

Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling expansion cohorts in defined tumor settings Initiated Phase 1 study of JANX011 in healthy volunteers Entered collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors Appointment of William Go, M.D., Ph.D., as Chief Medical Officer Strong year-end cash position supporting continued pipeline execution SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. “The past year marked a period of significant execution and progress for Janux as we continued to translate the pro...

26.02.26 - 21:06	Bristol Myers Says New Breast Cancer Drug Shows Survival Benefit In Pretreated Patients (Benzinga)
	Bristol Myers reports that Phase 3 breast cancer trial meets key goals, showing improved survival over chemotherapy options. Importance Rank: 1 read more...

26.02.26 - 13:57	Bristol Myers, SystImmune post late-stage trial win for breast cancer drug (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

25.02.26 - 15:12	Bristol Myers a new sector perform at RBC Capital Markets (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

23.02.26 - 08:31	Bristol Myers Squibb: Setzt sich die relative Stärke der Pharmaaktien fort? (LYNX)
	Nach der jüngsten Aufwärtsbewegung zeigt die Aktie von Bristol Myers Squibb eine Konsolidierung. Das Chartbild wirkt dabei weiterhin stabil....

21.02.26 - 20:24	Down 25%, Should You Buy the Dip on Bristol Myers Squibb? (Fool)
	The pharma industry's dreaded patent cliff is a key driver of the stock's decline....

20.02.26 - 20:03	What Analysts Are Saying About Bristol-Myers Squibb Stock (Benzinga)
	Latest Ratings for BMY DateFirmActionFromTo Mar 2022Wells FargoMaintainsEqual-Weight Dec 2021Goldman SachsInitiates Coverage OnBuy Dec 2021Wells FargoInitiates Coverage OnEqual-Weight View More Analyst Ratings for BMY View the Latest Analyst Ratings Importance Rank: 1 read more...

20.02.26 - 19:46	Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? (Zacks)
	BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor....

18.02.26 - 19:00	FDA Accepts BMY′s NDA for Iberdomide Combo in Multiple Myeloma (Zacks)
	FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026....

17.02.26 - 23:33	Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) \| DelveInsight (PR Newswire)
	The juvenile idiopathic arthritis market is experiencing steady growth driven by rising disease awareness, improved diagnostic capabilities, and expanding access to advanced biologic therapies. Additionally, the launch of emerging therapies such as SOTYKTU (Bristol-Myers Squibb), BIMZELX......

17.02.26 - 20:18	Bristol Myers wins FDA priority review for multiple myeloma therapy (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.02.26 - 20:06	What Does the Market Think About Bristol-Myers Squibb Co? (Benzinga)
	Importance Rank: 1 read more...

11.02.26 - 23:33	EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) \| DelveInsight (PR Newswire)
	The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb),......

11.02.26 - 13:03	Bristol-Myers Squibb Company: Robert A. Winn Excellence in Clinical Trials Award Program Announces Third Cohort of Physician-Researchers for the Clinical Investigator Leadership Award (Accesswire)
	Bristol Myers Squibb Foundation is proud to support Conquer Cancer's EveryGrant and the American Heart Association to Advance Clinical Trials Leadership in Oncology and Cardiovascular ResearchOrigi......

06.02.26 - 00:09	Bristol-Myers Squibb outlines $46B–$47.5B 2026 revenue target as growth portfolio nears 60% of sales, driven by new product launches and pipeline catalysts (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.02.26 - 23:36	Why Bristol Myers Squibb Stock Topped the Market Today (Fool)
	At the end of last year, the company did particularly well with its lineup of newer medications....

05.02.26 - 18:15	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
	BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs....

05.02.26 - 16:54

Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn’t Even Hit Yet (24/7 Wall St.)

Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion. The pharmaceutical giant delivered non-GAAP EPS of $1.26 for the quarter, which included a $(0.60) impact from Orbital Therapeutics acquisition charges. The company announced results on Thursday, February 5, 2026, before market open. Growth ... Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet The post Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet appeared first on 24/7 Wall St.....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Froher Mut braucht keinen Doktor. - Sprichwort Deutschland

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram